Nifty

:

22573.50

Sensex

:

74305.02

171.10 (0.76%)
452.08 (0.61%)

Login

Nifty
Sensex

:
:

22573.50
74305.02

171.10 (0.76%)
452.08 (0.61%)

Gland Pharma Ltd.

Pharmaceuticals & Drugs

Rating :

48/99

BSE: 543245 | NSE: GLAND

Watchlist

NSE BSE

1756.70

24-Apr-2024

Open
High
Low
Previous Close

1797.00
1797.00
1747.30
1781.90

Volume
Traded Value (lacs)
52 Week High
52 Week Low

89617
1591.97
2194.00
861.00

Stock Summary

Market Cap(Crs)
Stock P:E
Face Value

28,947.05
43.94
1

Enterprise Value(Crs)
Dividend Yield
Price:Book Value

27,115.03
N/A
3.41

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

10 Years
5 Years
3 Years

13.82
12.09
1.53

EBITDA CAGR (%)

10 Years
5 Years
3 Years

10.94
7.60
-4.68

PAT CAGR (%)

10 Years
5 Years
3 Years

13.23
11.41
-7.81

P:E (Median)

8 Years
5 Years
3 Years

-
-
37.37

P:BV (Average)

8 Years
5 Years
3 Years

-
-
5.17

EV:EBITDA (Average)

8 Years
5 Years
3 Years

-
-
23.43

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone

Description Dec 23 Dec 22 Var% Sep 23 Sep 22 Var% Jun 23 Jun 22 Var% Mar 23 Mar 22 Var%
Net Sales 1,097.86 925.90 18.57% 1,010.67 1,048.31 -3.59% 884.07 856.90 3.17% 785.42 1,103.01 -28.79%
Expenses 728.37 641.94 13.46% 663.57 753.07 -11.88% 624.71 586.69 6.48% 616.27 754.58 -18.33%
EBITDA 369.49 283.96 30.12% 347.10 295.24 17.57% 259.36 270.20 -4.01% 169.15 348.43 -51.45%
EBIDTM 33.66% 30.67% 34.34% 28.16% 29.34% 31.53% 21.54% 31.59%
Other Income 43.39 61.51 -29.46% 41.11 65.62 -37.35% 35.21 74.39 -52.67% 38.94 65.23 -40.30%
Interest 0.80 2.62 -69.47% 0.91 1.72 -47.09% 1.60 0.90 77.78% 2.18 2.03 7.39%
Depreciation 40.33 37.61 7.23% 40.24 36.67 9.74% 38.98 34.91 11.66% 37.54 31.07 20.82%
PBT 371.75 305.24 21.79% 347.06 322.47 7.63% 253.99 308.78 -17.74% 111.91 380.56 -70.59%
Tax 94.95 77.70 22.20% 89.54 82.84 8.09% 66.41 79.33 -16.29% 32.70 94.58 -65.43%
PAT 276.81 227.54 21.65% 257.53 239.63 7.47% 187.58 229.45 -18.25% 79.21 285.98 -72.30%
PATM 25.21% 24.57% 25.48% 22.86% 21.22% 26.78% 10.08% 25.93%
EPS 16.81 13.82 21.64% 15.64 14.55 7.49% 11.39 13.93 -18.23% 4.81 17.36 -72.29%

Description Dec 23 Dec 22 Var% Sep 23 Sep 22 Var% Jun 23 Jun 22 Var% Mar 23 Mar 22 Var%
Net Sales 1,545.15 938.29 64.68% 1,373.42 1,044.40 31.50% 1,208.69 856.90 41.05% 785.01 1,103.01 -28.83%
Expenses 1,188.76 648.72 83.25% 1,049.35 747.55 40.37% 914.74 586.98 55.84% 616.59 754.66 -18.30%
EBITDA 356.39 289.57 23.08% 324.08 296.85 9.17% 293.95 269.92 8.90% 168.42 348.36 -51.65%
EBIDTM 23.07% 30.86% 23.60% 28.42% 24.32% 31.50% 21.45% 31.58%
Other Income 37.39 61.51 -39.21% 53.15 65.62 -19.00% 37.54 74.39 -49.54% 38.94 65.23 -40.30%
Interest 5.28 2.62 101.53% 6.05 1.72 251.74% 4.92 0.90 446.67% 2.20 2.03 8.37%
Depreciation 105.34 37.61 180.09% 81.30 36.67 121.71% 65.31 34.91 87.08% 37.54 31.07 20.82%
PBT 283.16 310.85 -8.91% 289.89 324.08 -10.55% 261.27 308.50 -15.31% 111.15 380.48 -70.79%
Tax 91.30 78.90 15.72% 95.81 82.84 15.66% 67.16 79.33 -15.34% 32.47 94.58 -65.67%
PAT 191.86 231.95 -17.28% 194.08 241.24 -19.55% 194.10 229.17 -15.30% 78.68 285.90 -72.48%
PATM 12.42% 24.72% 14.13% 23.10% 16.06% 26.74% 10.02% 25.92%
EPS 11.65 14.08 -17.26% 11.78 14.65 -19.59% 11.79 13.92 -15.30% 4.78 17.40 -72.53%

Annual Results

Standalone Figures in Rs. Crores /

Consolidated

Right to Left

Description TTM Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15 Mar 14
Net Sales 3,778.02 3,616.53 4,400.71 3,462.88 2,633.24 2,044.20 1,619.94 1,479.18 1,347.87 993.80 990.92 Net Sales Growth -3.97% -17.82% 27.08% 31.51% 28.82% 26.19% 9.52% 9.74% 35.63% 0.29% Cost Of Goods Sold 1,668.48 1,685.42 2,109.22 1,219.00 836.07 626.35 479.75 375.07 540.21 414.04 412.46 Gross Profit 2,109.54 1,931.10 2,291.49 2,243.88 1,797.18 1,417.85 1,140.18 1,104.11 807.66 579.75 578.46 GP Margin 55.84% 53.40% 52.07% 64.80% 68.25% 69.36% 70.38% 74.64% 59.92% 58.34% 58.38% Total Expenditure 2,632.92 2,597.98 2,890.07 2,160.61 1,677.77 1,337.89 1,084.84 854.19 845.63 677.60 630.31 Power & Fuel Cost - 124.84 95.05 74.58 78.50 74.03 60.35 49.24 46.96 42.72 36.07 % Of Sales - 3.45% 2.16% 2.15% 2.98% 3.62% 3.73% 3.33% 3.48% 4.30% 3.64% Employee Cost - 399.70 338.57 311.36 277.66 222.95 179.08 153.42 131.30 105.69 81.44 % Of Sales - 11.05% 7.69% 8.99% 10.54% 10.91% 11.05% 10.37% 9.74% 10.63% 8.22% Manufacturing Exp. - 194.21 179.85 436.84 391.88 337.81 269.23 217.13 72.95 62.42 56.70 % Of Sales - 5.37% 4.09% 12.61% 14.88% 16.53% 16.62% 14.68% 5.41% 6.28% 5.72% General & Admin Exp. - 119.02 93.79 58.62 57.77 47.00 78.76 42.74 32.91 30.74 28.57 % Of Sales - 3.29% 2.13% 1.69% 2.19% 2.30% 4.86% 2.89% 2.44% 3.09% 2.88% Selling & Distn. Exp. - 30.26 40.98 36.69 17.08 13.88 9.93 11.40 15.80 16.41 12.18 % Of Sales - 0.84% 0.93% 1.06% 0.65% 0.68% 0.61% 0.77% 1.17% 1.65% 1.23% Miscellaneous Exp. - 44.53 32.61 23.51 18.82 15.86 7.73 5.19 5.52 5.58 12.18 % Of Sales - 1.23% 0.74% 0.68% 0.71% 0.78% 0.48% 0.35% 0.41% 0.56% 0.29% EBITDA 1,145.10 1,018.55 1,510.64 1,302.27 955.47 706.31 535.10 624.99 502.24 316.20 360.61 EBITDA Margin 30.31% 28.16% 34.33% 37.61% 36.28% 34.55% 33.03% 42.25% 37.26% 31.82% 36.39% Other Income 158.65 240.46 223.94 134.78 139.17 85.56 48.79 33.56 36.76 29.65 8.54 Interest 5.49 7.41 5.24 3.41 7.18 3.56 4.13 6.39 16.42 16.69 13.38 Depreciation 157.09 146.74 110.30 98.78 94.59 81.96 78.21 74.15 63.46 56.72 28.42 PBT 1,084.71 1,104.86 1,619.04 1,334.85 992.87 706.36 501.56 578.01 459.11 272.43 327.34 Tax 283.60 272.58 406.89 337.85 220.01 234.45 180.45 164.28 145.51 63.16 103.47 Tax Rate 26.15% 26.00% 25.13% 25.31% 22.16% 34.16% 35.98% 28.42% 31.69% 23.18% 31.61% PAT 801.13 775.83 1,212.15 997.00 772.86 451.91 321.11 413.73 313.61 209.27 223.88 PAT before Minority Interest 801.13 775.83 1,212.15 997.00 772.86 451.91 321.11 413.73 313.61 209.27 223.88 Minority Interest 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 PAT Margin 21.21% 21.45% 27.54% 28.79% 29.35% 22.11% 19.82% 27.97% 23.27% 21.06% 22.59% PAT Growth -18.47% -36.00% 21.58% 29.00% 71.02% 40.73% -22.39% 31.93% 49.86% -6.53% EPS 48.64 47.11 73.60 60.53 46.93 27.44 19.50 25.12 19.04 12.71 13.59

Description TTM Mar 23 Mar 22 Mar 21 Mar 20
Net Sales 4,912.27 3,624.60 4,400.71 3,462.88 2,633.24 Net Sales Growth 24.59% -17.64% 27.08% 31.51% Cost Of Goods Sold 1,938.53 1,685.42 2,109.11 1,219.00 836.07 Gross Profit 2,973.74 1,939.17 2,291.60 2,243.88 1,797.18 GP Margin 60.54% 53.50% 52.07% 64.80% 68.25% Total Expenditure 3,769.44 2,599.84 2,890.56 2,160.65 1,677.77 Power & Fuel Cost - 124.84 95.05 74.58 78.50 % Of Sales - 3.44% 2.16% 2.15% 2.98% Employee Cost - 403.26 338.57 311.36 277.66 % Of Sales - 11.13% 7.69% 8.99% 10.54% Manufacturing Exp. - 194.23 179.85 436.84 391.88 % Of Sales - 5.36% 4.09% 12.61% 14.88% General & Admin Exp. - 120.53 94.28 58.66 57.77 % Of Sales - 3.33% 2.14% 1.69% 2.19% Selling & Distn. Exp. - 27.03 40.98 36.69 17.08 % Of Sales - 0.75% 0.93% 1.06% 0.65% Miscellaneous Exp. - 44.53 32.72 23.51 18.82 % Of Sales - 1.23% 0.74% 0.68% 0.71% EBITDA 1,142.84 1,024.76 1,510.15 1,302.23 955.47 EBITDA Margin 23.27% 28.27% 34.32% 37.61% 36.28% Other Income 167.02 240.46 223.94 134.78 139.17 Interest 18.45 7.45 5.24 3.41 7.18 Depreciation 289.49 146.74 110.30 98.78 94.59 PBT 945.47 1,111.04 1,618.55 1,334.81 992.87 Tax 286.74 273.54 406.89 337.85 220.01 Tax Rate 30.33% 25.94% 25.14% 25.31% 22.16% PAT 658.72 781.04 1,211.66 996.96 772.86 PAT before Minority Interest 658.72 781.04 1,211.66 996.96 772.86 Minority Interest 0.00 0.00 0.00 0.00 0.00 PAT Margin 13.41% 21.55% 27.53% 28.79% 29.35% PAT Growth -33.35% -35.54% 21.54% 29.00% EPS 40.00 47.42 73.57 60.53 46.93

Results Balance Sheet

Standalone Figures in Rs. Crores /

Consolidated

Right to Left

Description Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15 Mar 14
Shareholder's Funds 7,953.30 7,158.23 5,903.28 3,646.24 2,862.11 2,410.42 2,089.81 1,677.07 1,394.19 833.65 Share Capital 16.47 16.43 16.36 15.49 15.49 15.49 15.49 15.49 15.67 11.76 Total Reserves 7,935.16 7,128.56 5,861.51 3,614.26 2,846.62 2,394.93 2,074.32 1,661.57 1,378.52 821.89 Non-Current Liabilities 89.68 93.97 80.31 80.78 127.79 139.37 130.55 121.95 119.76 132.29 Secured Loans 0.00 0.00 0.00 0.00 0.00 0.00 0.00 50.17 70.49 85.36 Unsecured Loans 3.26 3.82 3.93 4.07 4.96 5.49 5.92 6.37 6.67 6.94 Long Term Provisions 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.41 Current Liabilities 730.20 581.94 512.46 359.02 532.68 378.55 253.38 287.29 244.18 320.66 Trade Payables 589.42 462.76 396.28 249.09 446.20 292.42 189.29 88.51 65.57 98.47 Other Current Liabilities 109.46 76.42 62.36 81.73 72.60 71.13 61.87 151.77 119.60 162.99 Short Term Borrowings 0.00 0.00 0.00 0.00 0.00 0.00 0.00 39.90 58.52 58.26 Short Term Provisions 31.32 42.75 53.82 28.20 13.88 15.01 2.23 7.12 0.50 0.92 Total Liabilities 8,773.18 7,834.14 6,496.05 4,086.04 3,522.58 2,928.34 2,473.74 2,086.31 1,758.13 1,286.60 Net Block 1,570.55 1,502.19 954.23 968.10 928.74 842.64 871.58 787.88 648.63 459.74 Gross Block 2,294.95 2,081.32 1,430.70 1,347.81 1,219.58 1,054.45 1,005.52 1,020.22 820.49 565.31 Accumulated Depreciation 724.41 579.13 476.46 379.71 290.83 211.81 133.94 232.34 171.86 105.57 Non Current Assets 1,884.84 1,989.70 1,372.99 1,239.75 1,165.13 1,077.36 1,065.60 1,014.41 902.65 689.53 Capital Work in Progress 177.22 190.75 337.81 188.47 123.16 198.88 161.15 202.10 192.08 207.88 Non Current Investment 8.16 8.16 0.55 0.00 0.00 0.00 0.00 0.17 0.17 0.05 Long Term Loans & Adv. 128.92 286.40 77.97 81.52 111.89 33.89 29.42 21.63 54.86 21.51 Other Non Current Assets 0.00 2.21 2.43 1.66 1.33 1.95 3.44 2.62 6.92 0.35 Current Assets 6,888.34 5,844.44 5,123.07 2,846.29 2,357.46 1,850.98 1,408.15 1,071.90 855.48 597.06 Current Investments 0.00 154.87 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Inventories 1,945.30 1,185.67 1,275.17 756.28 911.88 512.83 378.72 367.08 321.19 306.36 Sundry Debtors 862.84 1,074.81 670.97 601.78 506.10 475.21 417.87 350.69 169.31 168.20 Cash & Bank 3,767.00 3,085.80 3,005.20 1,325.19 753.35 670.84 533.08 273.23 315.63 77.10 Other Current Assets 313.20 96.75 84.12 71.23 186.13 192.10 78.48 80.91 49.35 45.40 Short Term Loans & Adv. 222.37 246.55 87.60 91.80 131.94 126.45 30.20 36.37 17.71 20.04 Net Current Assets 6,158.14 5,262.50 4,610.61 2,487.27 1,824.78 1,472.43 1,154.77 784.61 611.30 276.41 Total Assets 8,773.18 7,834.14 6,496.06 4,086.04 3,522.59 2,928.34 2,473.75 2,086.31 1,758.13 1,286.59

Description Mar 23 Mar 22 Mar 21 Mar 20
Shareholder's Funds 7,958.72 7,157.62 5,903.24 3,646.24 Share Capital 16.47 16.43 16.36 15.49 Total Reserves 7,940.59 7,127.95 5,861.46 3,614.26 Non-Current Liabilities 89.68 93.97 80.31 80.78 Secured Loans 0.00 0.00 0.00 0.00 Unsecured Loans 3.26 3.82 3.93 4.07 Long Term Provisions 0.00 0.00 0.00 0.00 Current Liabilities 729.13 582.02 512.53 359.02 Trade Payables 587.35 462.85 396.35 249.09 Other Current Liabilities 109.48 76.42 62.36 81.73 Short Term Borrowings 0.00 0.00 0.00 0.00 Short Term Provisions 32.30 42.75 53.82 28.20 Total Liabilities 8,777.53 7,833.61 6,496.08 4,086.04 Net Block 1,570.55 1,502.19 954.23 968.10 Gross Block 2,294.95 2,081.32 1,430.70 1,347.81 Accumulated Depreciation 724.41 579.13 476.46 379.71 Non Current Assets 1,876.73 1,981.54 1,372.44 1,239.75 Capital Work in Progress 177.22 190.75 337.81 188.47 Non Current Investment 0.00 0.00 0.00 0.00 Long Term Loans & Adv. 128.96 286.40 77.97 81.52 Other Non Current Assets 0.00 2.21 2.43 1.66 Current Assets 6,900.81 5,852.08 5,123.64 2,846.29 Current Investments 0.00 154.87 0.00 0.00 Inventories 1,945.30 1,185.67 1,275.17 756.28 Sundry Debtors 871.39 1,074.81 670.97 601.78 Cash & Bank 3,770.68 3,093.44 3,005.75 1,325.19 Other Current Assets 313.44 96.75 84.15 71.23 Short Term Loans & Adv. 222.44 246.55 87.60 91.80 Net Current Assets 6,171.68 5,270.05 4,611.11 2,487.27 Total Assets 8,777.54 7,833.62 6,496.08 4,086.04

Cash Flow

Standalone Figures in Rs. Crores /

Consolidated

Right to Left

Description Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15 Mar 14
Cash From Operating Activity 367.89 791.29 604.93 700.93 185.06 201.93 476.46 224.09 148.05 130.43 PBT 1,048.40 1,619.04 1,334.85 992.87 686.36 501.56 578.01 459.11 272.43 327.34 Adjustment 37.38 -28.19 17.30 32.15 76.12 50.94 70.69 68.72 56.67 42.93 Changes in Working Capital -407.00 -393.05 -435.80 -79.94 -353.94 -193.43 -10.86 -187.17 -117.14 -148.29 Cash after chg. in Working capital 678.78 1,197.80 916.36 945.07 408.53 359.07 637.85 340.66 211.96 221.98 Interest Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Tax Paid -310.89 -406.51 -311.43 -244.14 -223.47 -157.14 -161.39 -116.56 -63.91 -91.55 Other Direct Exp. Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Extra & Other Items 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Cash From Investing Activity 1,208.22 -1,010.23 -1,524.55 -766.08 -314.14 -358.84 -96.65 -11.91 -399.89 -190.31 Net Fixed Assets -200.10 -503.56 -232.23 -193.54 -89.41 -86.66 55.65 -209.75 -239.38 -179.39 Net Investments 154.87 -162.48 -0.55 0.00 0.00 0.00 0.17 0.00 -0.12 0.00 Others 1,253.45 -344.19 -1,291.77 -572.54 -224.73 -272.18 -152.47 197.84 -160.39 -10.92 Cash from Financing Activity 14.92 34.90 1,238.46 -6.87 -2.93 -3.59 -116.42 -92.90 333.48 45.60 Net Cash Inflow / Outflow 1,591.04 -184.04 318.84 -72.01 -132.01 -160.50 263.39 119.29 81.64 -14.28 Opening Cash & Equivalents 311.18 491.92 169.50 236.40 372.84 533.08 273.23 157.81 76.04 90.33 Closing Cash & Equivalent 1,905.22 311.18 491.92 169.50 236.40 372.84 533.08 273.23 157.81 76.04

Description Mar 23 Mar 22 Mar 21 Mar 20
Cash From Operating Activity 363.97 790.77 604.93 700.93 PBT 1,054.58 1,618.55 1,334.81 992.87 Adjustment 38.19 -28.27 17.30 32.15 Changes in Working Capital -417.94 -393.01 -435.76 -79.94 Cash after chg. in Working capital 674.83 1,197.28 916.35 945.07 Interest Paid 0.00 0.00 0.00 0.00 Tax Paid -310.87 -406.51 -311.43 -244.14 Other Direct Exp. Paid 0.00 0.00 0.00 0.00 Extra & Other Items 0.00 0.00 0.00 0.00 Cash From Investing Activity 1,208.19 -1,002.62 -1,524.00 -766.08 Net Fixed Assets -200.10 -503.56 -232.23 Net Investments 154.87 -162.48 -0.55 Others 1,253.42 -336.58 -1,291.22 Cash from Financing Activity 14.92 34.90 1,238.46 -6.87 Net Cash Inflow / Outflow 1,587.08 -176.95 319.39 -72.01 Opening Cash & Equivalents 318.82 492.46 169.50 236.40 Closing Cash & Equivalent 1,908.89 318.82 492.46 169.50

Financial Ratios

Standalone /

Consolidated

Right to Left

Description Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15 Mar 14
Book Value (Rs.) 482.80 434.87 359.30 234.25 1847.12 1555.61 1348.70 1082.33 889.58 708.98 ROA 9.34% 16.92% 18.84% 20.32% 14.01% 11.89% 18.15% 16.31% 13.75% 20.31% ROE 10.28% 18.62% 20.97% 23.81% 17.14% 14.27% 21.97% 20.42% 18.79% 31.02% ROCE 13.97% 24.86% 28.00% 30.68% 26.11% 22.41% 30.04% 28.35% 22.50% 39.05% Fixed Asset Turnover 1.65 2.51 2.49 2.05 1.80 1.58 1.47 1.47 1.45 2.10 Receivable days 97.78 72.40 67.08 76.78 87.61 100.43 94.03 69.91 61.50 54.15 Inventory Days 158.00 102.05 107.06 115.61 127.19 100.26 91.25 92.53 114.35 86.69 Payable days 113.93 74.33 96.62 73.57 99.56 79.68 57.64 32.44 46.12 39.56 Cash Conversion Cycle 141.84 100.12 77.52 118.83 115.24 121.01 127.64 129.99 129.73 101.28 Total Debt/Equity 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.07 0.12 0.21 Interest Cover 142.41 309.98 392.34 139.24 193.80 122.59 91.43 28.97 17.32 25.47

Description Mar 23 Mar 22 Mar 21 Mar 20
Book Value (Rs.) 483.12 434.84 359.30 234.25 ROA 9.40% 16.91% 18.84% 18.91% ROE 10.34% 18.61% 20.97% 21.29% ROCE 14.04% 24.85% 28.00% 27.39% Fixed Asset Turnover 1.66 2.51 2.49 1.95 Receivable days 97.99 72.40 67.08 83.41 Inventory Days 157.65 102.05 107.06 104.83 Payable days 113.72 74.35 96.63 52.71 Cash Conversion Cycle 141.92 100.10 77.51 135.53 Total Debt/Equity 0.00 0.00 0.00 0.00 Interest Cover 142.61 309.77 392.33 139.24

Top Investors:

mirae asset large & midcap fund

nippon life india trustee ltd-a/c nippon india small cap fund

rp advisory services private limited

sbi large & midcap fund

hdfc mutual fund - hdfc mid-cap opportunities fund

uti flexi cap fund

icici prudential equity & debt fund

nicomac machinery private limited

Annual Reports:

News Update:

Gland Pharma gets USFDA’s approval for Eribulin Mesylate Injection
8th Apr 2024, 10:44 AM

The company expects to launch this product in the near term through its marketing partner
Read More
Gland Pharma - Quarterly Results
14th Feb 2024, 16:19 PM

Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.

Feedback